MBX
MBX clinical trials: MBX Biosciences, Inc.
Every trial on ClinicalTrials.gov where MBX Biosciences, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 8
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
MBX on the catalyst calendar · MBX registry changes
- Primary completion Jan 2028Sponsor estimatePhase 3NCT07699471A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With HypoparathyroidismMBX Biosciences · HypoparathyroidismRecruitingMBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2028Sponsor estimatePhase 2NCT06531941Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With HypoparathyroidismMBX Biosciences · HypoparathyroidismActive, not recruitingMBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 18, 2026ActualPhase 2NCT07029412Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)MBX Biosciences · Postbariatric HypoglycemiaCompletedMBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2026Sponsor estimatePhase 1NCT07142707A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With ObesityMBX Biosciences · ObesityRecruitingMBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 23, 2025ActualPhase 2NCT06465108Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With HypoparathyroidismMBX Biosciences · HypoparathyroidismCompletedMBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 4, 2025ActualPhase 1NCT06496217Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal FunctionMBX Biosciences · Renal ImpairmentCompletedMBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 14, 2024ActualPhase 1NCT06036784Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy SubjectsMBX Biosciences · Postbariatric HypoglycemiaCompletedMBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 20, 2023ActualPhase 1NCT05158335Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult SubjectsMBX Biosciences · HealthyCompletedMBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner